Difference between revisions of "Pidilizumab (CT-011)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| − | + | =Mechanism of action= | |
| − | == | + | =Preliminary data= |
| − | + | ==[[Diffuse large B-cell lymphoma]]== | |
| − | |||
| − | |||
| − | |||
| − | |||
===Regimen=== | ===Regimen=== | ||
| Line 26: | Line 22: | ||
'''42-day cycle x 3 cycles''' | '''42-day cycle x 3 cycles''' | ||
| − | + | ===References=== | |
| + | # Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Kent Holland H, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. J Clin Oncol. 2013 Oct 14. [Epub ahead of print] [http://jco.ascopubs.org/content/31/33/4199.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/24127452 PubMed] | ||
| − | == | + | ==[[Follicular lymphoma]]== |
| − | |||
# Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70551-5/fulltext?elsca1=ETOC-ONCOLOGY&elsca2=email&elsca3=P24A35F link to original article] Epub 2013 Dec 11. [http://www.ncbi.nlm.nih.gov/pubmed/24332512 PubMed] | # Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70551-5/fulltext?elsca1=ETOC-ONCOLOGY&elsca2=email&elsca3=P24A35F link to original article] Epub 2013 Dec 11. [http://www.ncbi.nlm.nih.gov/pubmed/24332512 PubMed] | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | |||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
| − | [[Category:Anti-PD-1 | + | [[Category:Antibody medications |
| + | [[Category:Anti-PD-1 antibodies]] | ||
[[Category:Aggressive Non-Hodgkin lymphoma medications]] | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
Revision as of 22:40, 26 November 2014
Mechanism of action
Preliminary data
Diffuse large B-cell lymphoma
Regimen
Phase II
Treatment is to begin within 30 to 90 days after autologous stem-cell transplant for chemoresponsive disease.
- Pidilizumab (CT-011) 1.5 mg/kg IV once
Supportive medications:
- Acetaminophen (Tylenol) or Ibuprofen prior to Pidilizumab (CT-011)
- Diphenhydramine (Benadryl) or Promethazine (Phenergan) prior to Pidilizumab (CT-011)
42-day cycle x 3 cycles
References
- Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Kent Holland H, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. J Clin Oncol. 2013 Oct 14. [Epub ahead of print] link to original article contains verified protocol PubMed
Follicular lymphoma
- Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. link to original article Epub 2013 Dec 11. PubMed
[[Category:Antibody medications